Portal de Periódicos da CAPES

Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: A phase III study in Tanzania

2010; Elsevier BV; Volume: 28; Issue: 48 Linguagem: Inglês

10.1016/j.vaccine.2010.09.041

1873-2518

Timothy Lahey, Robert D. Arbeit, Muhammad Bakari, C. Robert Horsburgh, Mecky Matee, Richard Waddell, Lillian Mtei, Jenni M. Vuola, Kisali Pallangyo, C. Fordham von Reyn,

Immunodeficiency and Autoimmune Disorders

Preventive immunization with whole inactivated Mycobacterium vaccae (MV) confers protection against HIV-associated tuberculosis (TB) in BCG-immunized adults with CD4 counts ≥200 cells/μl. We evaluated the immunogenicity of MV in the 2013 subjects of the phase III DarDarTrial using an interferon gamma (IFN-γ) enzyme linked immunosorbent assay (ELISA), tritiated thymidine lymphocyte proliferation assay (LPA) and an ELISA for antibodies to the TB glycolipid lipoarabinomannan (LAM). MV immunization boosts IFN-γ and LPA responses to MV sonicate, and antibody responses to LAM. Post-immunization immune responses to MV correlated with baseline clinical factors, but the responses did not predict protection from HIV-associated TB.